Systematic Review of NK Cell Therapy Clinical Trials for AML

Letícia Dalla Vecchia Grassi's meta-analysis synthesizes data from 29 phase 1–2 clinical trials on NK cell adoptive transfer for acute myeloid leukemia. The review pools outcomes for 217 relapsed/refractory patients and 303 patients receiving combination therapy with haploidentical HSCT. It analyzes pooled response rates and one-year disease-free survival across different patient subgroups.

Use Cases

• Pool response rates for the 217 relapsed/refractory AML patients to evaluate NK monotherapy efficacy.
• Analyze one-year disease-free survival outcomes across high-risk AML and haploidentical HSCT combination therapy subgroups.
• Compare toxicity and graft-versus-host disease rates reported across the 29 included clinical trials.
• Assess heterogeneity metrics (I²) and publication bias from the meta-analysis methodology.

Strengths

• Systematic review methodology covering 790 identified records from PubMed and EMBASE (2000–2024).
• Quantitative meta-analysis provides pooled statistics, including a 35% response rate for 217 R/R AML patients.
• Clear assessment of study quality using the NIH before–after tool and evaluation of heterogeneity.

Limitations

• Data is presented only in a 324 KB PDF report, limiting direct computational analysis of underlying trial data.
• Included studies are predominantly single-arm phase I/II trials, with only one randomized phase II trial.
• Sample sizes for some subgroups are small, such as 38 patients in the low/intermediate-risk AML remission analysis.

Provenance

Source

Letícia Dalla Vecchia Grassi via figshare.

Collection Method

Systematic review and meta-analysis of published clinical trials.

Time Range

Clinical trials from 2000 to 2024.

Freshness

Last updated March 2026.

Geography

null